Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kathryn Beldowski

Geriatric Medicine Broomall, PA Medical Doctor

NPI 1487947487 CMS profile 1363526

30 Lawrence Rd Ste 500, Broomall, PA 19008

Open in the dashboard

General payments

$3,613

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathryn Beldowski of Broomall, PA is reported in the CMS Open Payments database as having received $3,613 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $356 14
2024 General $1,096 52
2023 General $898 48
2022 General $481 26
2021 General $138 6
2020 General $43 3
2019 General $601 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Beldowski
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Kathryn Beldowski were reported at $356. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Kathryn Beldowski Geriatric Medicine median Middle half National median
2019 $601 $122 $40–$435 $163
2020 $43 $98 $25–$349 $114
2021 $138 $125 $34–$441 $132
2022 $481 $124 $36–$408 $149
2023 $898 $121 $41–$383 $160
2024 $1,096 $134 $41–$435 $164
2025 $356 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $464 25 payments
  2. Novo Nordisk Inc $331 18 payments
  3. Teva Pharmaceuticals USA, Inc. $293 16 payments
  4. Otsuka America Pharmaceutical, Inc. $287 14 payments
  5. Novartis Pharmaceuticals Corporation $232 13 payments
  6. GlaxoSmithKline, LLC. $213 9 payments
  7. Janssen Pharmaceuticals, Inc $173 9 payments
  8. Eisai Inc. $140 5 payments
  9. Sumitomo Pharma America, Inc. $139 8 payments
  10. Avanir Pharmaceuticals, Inc. $134 4 payments
  11. Other $1,207 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,608 177 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $288 15 payments
  2. MOUNJARO $283 15 payments
  3. Ozempic $275 14 payments
  4. REXULTI $243 11 payments
  5. AUSTEDO $199 10 payments
  6. INVOKANA $173 9 payments
  7. TRELEGY ELLIPTA $162 6 payments
  8. XARELTO $151 7 payments
  9. ENTRESTO $142 8 payments
  10. Leqembi $140 5 payments
  11. Other $2,585 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 171 drugs

Part D claims

11,684

Median for Internal Medicine: 777

Drug cost

$904,813

Median for Internal Medicine: $73,373

Branded share of claims

22.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 283 $121,940
Jardiance Empagliflozin Brand 130 $71,395
Ozempic Semaglutide Brand 58 $69,266
Trulicity Dulaglutide Brand 49 $52,701
Xarelto Rivaroxaban Brand 110 $44,844
Januvia Sitagliptin Phosphate Brand 87 $44,574
Mounjaro Tirzepatide Brand 25 $28,495
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $26,070
Nuplazid Pimavanserin Tartrate Brand 11 $25,893
Myrbetriq Mirabegron Brand 102 $23,867

The 10 drugs with the highest cost, of 171 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$65,035

Of which drugs: $12,888

Medicare patients

347

Average age 78

Services billed

1,343

240 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Depression 33%
Osteoporosis 30%
Diabetes 28%
Chronic kidney disease 26%
Alzheimer's or dementia 25%
Ischemic heart disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 17 17 $4,919
Vaccine for influenza for injection into muscle 90662 Office 50 52 $4,205

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $114
  • Lundbeck LLC $54
$169 — —
MOUNJARO
  • Lilly USA, LLC $120
$120 25 —
INGREZZA
  • Neurocrine Biosciences, Inc. $94
$94 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $83
$83 36 —
JARDIANCE
  • Lilly USA, LLC $57
$57 130 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record